MIG Capital AG reported on the past financial year of their managed MIG funds. According to the report, a total of €172.5m was distributed to MIG investors from the sale of investments last year. Total distributions to MIG investors exceeded the one billion euro threshold for the first time.

This strong performance was again driven by BioNTech, but also by the successful sale of portfolio company Hemovent to MicroPort Surgical BV for a total price of up to €123m. Total payouts since the establishment of the first MIG Fonds thus increased to around €1.1bn.

To date, the investment company has launched 16 funds. Fundraising for the new MIG Fonds 16 closed at the end of the year at around €148 m. Currently, equity capital is being sought for Fund 17, which is to be about €160m.

The Mainz-based BioNTech, in which MIG achieved a record-breaking multiplication to distributed around €750m through an early entry with a double-digit million sum, is now no longer part of the portfolio according to the homepage and annual reports. The chapter seems to be – extremely successfully – closed. Michael Motschmann, General Partner of MIG Capital AG, noted: “Due to the strong performance of our portfolio, investors in several MIG funds were again able to benefit from substantial pay outs. A significant contribution to this came from the sale of our stake in BioNTech. Numerous MIG investors participated in the tremendous success of this company via MIG funds and were among the first investors in BioNTech. The progress made in our portfolio has also been very encouraging, with many operational milestones, successful exits and promising new investments. We are therefore confident to continue our growth trajectory in 2022.”

During the 2021 fiscal year, MIG Capital AG added new, highly innovative companies to its portfolio of managed funds: Zadient Technologies, Creative Balloons, iOmx therapeutixs and Mimi Hearing. These new investments, along with refinancing rounds in the existing portfolio, brought the total volume invested by MIG Fonds in the 2021 fiscal year to around €55m (previous year: €46m). In 2021, MIG Fonds and its co-investors raised a total of around €275m for MIG portfolio companies (previous year: €170m).

Michael Motschmann is optimistic about the future: “We see a strong deal flow in 2022 and remain committed to our strategic focus on young innovation leaders with breakthrough products based on cutting-edge technology and a compelling management team. The strong performance of many portfolio companies, which are now reaching more advanced stages, opens up attractive exit options. Finally, the broad expertise of our team, which includes engineers, physicists, biologists, and lawyers, gives us an important advantage in analyzing and evaluating companies in the biotech and deep tech sector. Even more crucially, we can identify the exceptional companies that combine both. Our experience with the unicorn BioNTech and other successful companies from our portfolio shows that convergent business models that combine two or more independent technologies into something truly innovative are key to successful investment decisions.”

MIG has invested in around 60 companies to date, with the current 30 portfolio companies spanning biopharmaceuticals, artificial intelligence/machine learning, quantum computing technologies, digitalization/IoT, precision medicine and digital health.